420 abstracts found.



Results filter

Elevated Parkinson’s-like tumour signalling from very early-stage colorectal cancer is associated with disease relapse

Year:

Session type:

Aoife McCooey1,Keara Redmond1,Emma Kerr1,Daniel Longley1,Philip Dunne1,S-cort Consortium2
1Queen's University Belfast,2S:CORT Consortium

PARP inhibition elicits tumour cell-intrinsic immune phenotypes in DNA repair deficient cancers.

Year:

Session type:

Roman Chabanon1,Gareth Muirhead2,Dragomir Krastev2,Julien Adam1,Marlène Garrido1,Daphné Morel1,Nicolas Dorvault1,Rebecca Marlow3,Alan Ashworth4,Stephen Pettitt2,Syed Haider2,Andrew Tutt2,Aurélien Marabelle1,Jean-Charles Soria5,Christopher Lord2,Sophie Postel-Vinay1
1Gustave Roussy,2Institute of Cancer Research,3King's College London,4UCSF Helen Diller Family Comprehensive Cancer Centre,5AstraZeneca/MedImmune

Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Year:

Session type:

Korsuk Sirinukunwattana1,Enric Domingo1,Susan Richman2,Keara Redmond3,Andrew Blake1,Clare Verrill1,Simon Leedham1,Katerina Chatzipli4,Claire Hardy4,Celina Whalley5,Chieh-Hsi Wu1,Andrew Beggs5,Ultan McDermott6,Philip Dunne3,Angela Meade7,Steven Walker8,Graeme Murray9,Leslie Samuel10,Matt Seymour11,Ian Tomlinson5,Philip Quirke2,Tim Maughan1,Jens Rittscher1,Viktor Koelzer12
1University of Oxford,2University of Leeds,3Queen's University Belfast,4Wellcome Sanger Institute,5University of Birmingham,6AstraZeneca,7University College London,8Almac Group Ltd,9University of Aberdeen,10NHS,11NIHR,12University of Zürich

Defining the role of AP-1 in molecular adaptation to hypoxia in colorectal cancer

Year:

Session type:

Eric VANCAUWENBERGHE1,Hannah Bolland2,Christopher Carroll2,Leonardo Da Motta2,Anna Grabowska3,Francesca Buffa4,Adrian Harris5,Alan McIntyre2
1Hypoxia and Tumour Microenvironment Group, Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham,2Hypoxia and Tumour Microenvironment Group, Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham,3Cancer Biology, Division of Cancer and Stem Cells, University of Nottingham, Medical School, Queen's Medical Centre, Nottingham, UK,4Computational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford, UK,5Molecular Oncology Laboratories, Department of Oncology, The Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.

Phenotyping neutrophil subpopulations in advanced lung cancer

Year:

Session type:

Robert Grecian1,Patricia Dos Santos Coelho1,Emily Watts1,Kev Dhaliwal1,Adam Byron1,Margaret Frame1,Moira Whyte1,Sarah Walmsley1
1Edinburgh University

Applicability of routine targeted next generation sequencing to estimate tumour mutational burden (TMB) in patients treated with immune-checkpoint inhibitor therapy

Year:

Session type:

Heather Urus1,David Pinato2,Thomas Newsom- Davis3,Persephone Du Parcq4,Katherine Belessiotis2,Leah Mapara2,Nandita Gupta5,Danielle Power2,Justin Weir5,Ching N Wong1,Ragu P Ratnakumaran2,Jamshid Khorashad4,Kathy Dominy4,Mark Bower3
1Department of Surgery & Cancer, Imperial College London,2Department of Oncology, Imperial College NHS Trust,3Department of Oncology, Chelsea & Westminster Hospital,4Molecular Pathology Laboratory, Hammersmith Hospital,5Department of Histopathology, Imperial College NHS Trust

Silvestrol sensitises breast cancer cells to radiation

Year:

Session type:

Thomas Webb1
1East Kent Hospitals University NHS Foundation Trust, Kent, UK

Identification and validation of natural anti-drug resistant and anticancer stem cell agents in TNBC stem cells

Year:

Session type:

Prem Kushwaha1,Shashank Kumar1
1Central University of Punjab, Punjab, India

Identifying metastatic disease via imaging pathways: could the radiology alerting system provide reliable information for cancer registries? A scoping project.

Year:

Session type:

Amy Sharkey1,Caroline Rubin2,Jeanette Dickson2,Jane Maher3,Vicky Goh4
1Macmillan Cancer Support, London, UK & Royal College of Radiologists, London, UK ,2Royal Collge of Radiologists,3Macmillan Cancer support,4Guy’s & St Thomas’ NHS Foundation Trust & King’s College London

Occupational exposure and smoking adjusted risk of bladder cancer. Population based cohort studies in the Nordic countries.

Year:

Session type:

Kishor Hadkhale1,Jan Ivar Martinsen2,Elisabete Weiderpass3,Kristina Kjaerheim2,Par Sparen4,Laufey Tryggvadottir5,Elsebeth Lynge6,Eero Pukkala7,Tom K Grimsrud2
1Tampere University, Tampere, Finland,2Cancer registry of Norway, Oslo, Norway,3International Agency for Research on Cancer, Lyon, France,4Karolinska Institute, Stockholm, Sweden,5Icelandic cancer registry, Reykjavik, Iceland,6University of Copenhagen, Copenhagen, Denmark,7Finnish cancer registry, Helsinki, Finland

Identifying people with multiple cancer diagnoses– a Scottish Routes from Diagnosis analysis

Year:

Session type:

Emily Moore1,Cheryl Denny1,Kelly Shiell-Davis2,Claire LeBlanc3
1Information Services Division, NHS National Services Scotland, Edinburgh, UK,2MacMillan Cancer Research, London, UK,3Macmillan Cancer Research, London, UK

The placebo response in trials of drug treatments for cancer-related fatigue: A systematic review, meta-analysis and meta-regression

Year:

Session type:

Maria del Rocio Roji Buqueras1,Patrick Stone2,Federico Ricciardi2,Bridget Candy2
1University College London, London, UK,2The Marie Curie Palliative Care Research Department, University College London, London, UK

Acceptability of circulating microRNAs for testicular germ cell malignancy: validation of an initial user consultation exercise

Year:

Session type:

Lorna Fern1,Michelle Greenwood2,Sue Brand3,Dan Stark4,Mathew Murray5
1University College London Hospitals,2St Bartholomew's Hospital London,3It’s in the Bag,4University of Leeds,5Cambridge University Hospitals

Yeast orthologue mapping predicts genetic vulnerabilities in tumour cells

Year:

Session type:

Mark Wade1,Kaliya Georgieva2,Christopher Hindley1,Harpreet Saini1
1Astex Pharmaceuticals,2University of Bath

Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup – the “ATRESS” phenomenon

Year:

Session type:

Patriek Jurrius1,Thomas Green1,Hans Garmo1,Matthew Young2,Massimilano Cariati1,Cheryl Gillett1,Anca Mera1,Mark Harries2,Anita Grigoriadis1,Sarah Pinder1,Lars Holmberg1,Arnie Purushotham1
1King's College London,2Guy’s and St Thomas NHS Foundation Trust

The Roles of Gelsolin in the Regulation of Wnt Signaling in Colorectal Cancer

Year:

Session type:

Mei Shan Ong1,Shuo Deng1,Tuan Zea Tan2,Shing Chuan Hooi1,Alan Prem Kumar3,Celestial T. Yap1
1National University of Singapore,2Cancer Science Institute,3National University of Singapore, Cancer Science Institute

Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in patients with metastatic colorectal cancer

Year:

Session type:

Jamal Zekri1,Ehab Mosaad2,Refaei Belal Ibrahim3,Kamel Mohamed Kamal4,Adnan Hussain5,Mohammed Abbas Baghdadi6
1College of Medicine, Al-Faisal University, King Faisal Specialist Hospital (Jeddah),2Medical oncology department, National Cancer Institute, Cairo University,3Department of clinical oncology and nuclear medicine. Faculty of medicine Al Azhar University,4Cairo University,5King Faisal Specialist Hospital and Research Center- Jeddah,6Research Centre, King Faisal Specialist Hospital & Research Centre, Jeddah

ORAI2 promotes tumorigenesis and metastasis in gastric cancer via activation of the PI3K/Akt and FAK/MAPK/ERK pathways

Year:

Session type:

Shayi Wu1
1University of Hong Kong

Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight >80 kg in REFLECT

Year:

Session type:

Arndt Vogel1,Masatoshi Kudo2,Ann-Lii Cheng3,Max W. Sung4,Richard S. Finn5,Albert Y. Lin6,Ghassan K. Abou-Alfa7,Angel Alsina8,Valeriy Breder9,Niall Tebbutt10,Pia Osterlund11,C. J. Yen12,Min Ren13,Soamnauth Misir13,Corina E. Dutcus13,Daniel Palmer14,Philippe Merle15,Matthias Pinter16,TR Jeffry Evans17
1Hannover Medical School,2Kindai University School of Medicine,3National Taiwan University Hospital,4Tisch Cancer Institute at Mount Sinai,5Geffen School of Medicine, UCLA Medical Center,6VA Palo Alto Health Care System,7Memorial Sloan Kettering Cancer Center,8Tampa General Hospital,9N.N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation,10Olivia Newton-John Cancer Centre,11Tampere University and Central Hospital,12National Cheng Kung University Hospital,13Eisai Inc.,14University of Liverpool, Liverpool,15CHU de Lyon -Hospital La Croix-Rousse,16Medical University of Vienna,17University of Glasgow

Carbonic Anhydrase 9 Confers Resistance to Ferroptosis/Apoptosis in Malignant Mesothelioma Under Hypoxia

Year:

Session type:

Zan Li1,Li Jiang1,Shinya Toyokuni1
1Nagoya University Graduate School of Medicine

Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model

Year:

Session type:

Pavlina Spiliopoulou1,Sarah Spear2,Patricia Roxburgh3,Susanne Dowson4,Susan Mason4,Karen Blyth4,Matthew Fuchter2,Bob Brown2,Iain A McNeish2
1Beatson West of Scotland Cancer Centre, Glasgow, UK,2Imperial College London, London, UK,3Beatson West of Scotland Cancer Centre,4University of Glasgow, Glasgow, UK

Assessing the immunomodulatory activity of cancer prevention agents using an ex vivo tumour explant model

Year:

Session type:

Sam Khan1,Ankur Karmokar1,Zahirah Sidat2,Nalini Foreman1,David Moore3,Anne Thomas1,Karen Brown1
1Leicester Cancer Research Centre, Robert Kilpatrick Clinical Sciences Building, University of Leicester, Leicester,2Hope Clinical Trials Facility, Leicester Royal Infirmary, Leicester,3University College London Hospitals NHS Foundation Trust, London

A novel role of BAP1 in regulating the spindle assembly checkpoint and mitotic spindle assembly

Year:

Session type:

Anita Singh1,Dean Fennell1,Andrew Fry1
1University of Leicester, Leicester, UK

Depressive symptoms and participation in breast and cervical cancer screening

Year:

Session type:

Claire Niedzwiedz1,Kathryn Robb1,Srinivasa Vittal Katikireddi1,Jill Pell1,Daniel Smith1
1University of Glasgow, Glasgow, UK

Health literacy and complex decision making in female breast cancer patients; understanding and misunderstanding in a consultation– scoping the views of clinicians

Year:

Session type:

Andrea Hilton1,Amandeep Dhadda2
1University of Hull,2Queens Centre for Oncology and Haematology, Hull University Teaching Hospitals NHS Trust, Hull

Is it possible to deliver an effective intervention in tackling fears of cancer recurrence ?

Year:

Session type:

Conor Wheeler1
1University of St. Andrew's, St. Andrew's, UK

Automatic 3D Segmentation of Head and Neck Tumours and Cancerous Lymph Nodes

Year:

Session type:

Baixiang Zhao1,John Soraghan1,Gaetano Di-caterina1,Derek Grose2
1university of strathclyde,2Beatson West of Scotland Cancer Centre

Pick-Seq®: a novel technology to retrieve tissue micro-regions for RNA sequencing

Year:

Session type:

Rebecca Podyminogin1,Nolan Ericson1,Jennifer Chow1,Jia-Ren Lin2,Yu-An Chen2,Zoltan Maliga2,Kyla Teplitz1,Tessa Pei-Ching Tsai1,Adrian Quintanilla1,Peter Sorger2,Eric Kaldjian1,Tad George1
1RareCyte, Seattle, US,2Harvard Medical School, Cambridge, US

Exploration of molecular signalling underpinning the DNA Damage Response Deficiency (DDRD) assay in Colorectal Cancer; Data from the S:CORT consortium (Stratification in COlorRecTal cancer)

Year:

Session type:

Sudhir Malla1,Keara Redmond1,Andrew Blake2,Enric Domingo2,Susan Richman3,Michael Youdell2,Ian Tomlinson4,Louise Brown5,Tim Maughan2,Mark Lawler1,Philip Dunne1,S:cort Consortium6
1Queen's University Belfast, Belfast, UK,2University of Oxford, Oxford, UK,3University of Leeds, Leeds, UK,4University of Birmingham, Birmingham, UK,5University College London, London, UK,6S:CORT Consortium, Oxford, UK

The impact of dietetic input in post radiotherapy head and neck cancer patients

Year:

Session type:

Robynne Cranston1,Nola Lynch1,Isobel Bowe1,Charles Kelly2,Shahid Iqbal2,Rachel A Pearson3
1Nutrition and Dietetics Department, Freeman Hospital, NHS Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK,2Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK,3 Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK, Newcastle University, Newcastle upon Tyne, UK

PARP inhibition causes replication stress in preclinical models of high risk neuroblastoma and synergises with inhibition of ATR

Year:

Session type:

Harriet Southgate1,Nicola J Curtin1,Deborah A Tweddle1
1Newcastle University, Newcastle, UK

The continual reassessment method for phase I clinical trial design: is it always more efficient than the 3+3?

Year:

Session type:

Samantha Hinsley1
1Clinical Trials Unit, Cancer Research UK, Glasgow, UK

Explaining socio-economic differences in bladder cancer survival

Year:

Session type:

Beth Russell1,Mieke Van Hemelrijck1,Truls Gårdmark2,Lars Holmberg1,Pardeep Kumar3,Andrea Bellavia4,Christel Häggström5
1King's College London, London, UK,2Karolinska Institute, Stockholm, Sweden,3Royal Marsden NHS Foundation Trust, London, UK,4Havard T.H Chan School of Public Health, Boston, US,5Uppsala University, Uppsala, Sweden

Deciphering the molecular signalling underpinning early-dissemination and metastasis from stage I colorectal cancer

Year:

Session type:

Philip Dunne1,Maurice Loughrey2,Helen Coleman2,Aoife McCooey2,Susan Richman3,Andrew Blake4,Keara Redmond2,Dion Morton5,Ian Tomlinson5,Simon Leedham4,Rachael McBride2,Jeffrey Campbell2,Tim Maughan4,Mark Lawler2,S:cort Consortium6
1Centre for Cancer Research & Cell Biology Queen's University Belfast, Belfast, UK ,2Queen's University Belfast, Belfast, UK,3University of Leeds, Leeds, UK,4University of Oxford, Oxford, UK,5University of Birmingham, Birmingham, UK,6S:CORT Consortium, Oxford, UK

Patient Perspective of Experimental Cancer Medicine (PpExCaM Survey) – a Patient-led Initiative to Understand the Views of Participating in Early-Phase Trials

Year:

Session type:

Mekala Gunaratnam1,Emma Hainsworth1,Terry Emmery2,Tim Meyer1
1University College London Cancer Institute, London, UK,2Patient participant

Factors associated with Emergency Admissions for Cancer Patients in Last year of life in a UK region

Year:

Session type:

Victoria Cairnduff1,Laura Dwyer1,Colin Fox1,Gregory Fallica2,Kelly Shiell-Davis3,Anna Gavin1
1Northern Ireland Cancer Registry, Belfast, UK,2Macmillan Cancer Support,3Macmillan Cancer Support, London, UK

The p53/p21 axis suppresses 5FU-induced, ATM/ATR-STAT3-mediated activation of PD-L1

Year:

Session type:

Tamas Sessler1,Fiammetta Falcone2,Peter Gallagher2,Daniel Longley2,Simon McDade2
1Centre for Cancer Research & Cell Biology Queen's University Belfast, Belfast, UK, Forensic Geoscience Group Queen's University Belfast, Belfast, UK,2Queen's University Belfast, Belfast, UK

Loss of BCL-3 expression increases sensitivity to irradiation induced DNA damage in colorectal cancer cells

Year:

Session type:

Christopher Parker1,Adam Chambers1,Ann Williams1
1University of Bristol, Bristol, UK

FGF1 and HSP27 Interact to Modulate the DNA Damage Response in Chemoresistant Ovarian Cancer Cells

Year:

Session type:

Hugh A. Nicholson1,Michelle J. Ferguson2,Gillian Smith1
1University of Dundee,2NHS Tayside

Re-audit on screen failures in early phase cancer clinical trials; a single institution experience

Year:

Session type:

Sreeja Aruketty1,Joanna Clarke2,Daniel Lovelle Gomez2,Dilshad Chang2,Alison White2,Matthew Krebs2,Louise Carter2,Donna Graham2,Shaun Villa2,Fiona Thistlethwaite2,Amanda Rees2,Natalie Cook2
1Experimental Cancer Medicine Team, The Christie NHS Trust,2Experimental Cancer Medicine Team, The Christie NHS Foundation Trust

Identifying health workers’ knowledge and beliefs regarding cervical cancer and screening, and its impact on screening utilisation in Gujarat, India

Year:

Session type:

Amanpreet Mundair1
1University of Leeds

Safety and Efficacy of Combined Metronomic Capecitabine with Aromatase Inhibitors for Patients with Newly Diagnosed Metastatic Hormone Positive, HER2 Negative Breast Cancer

Year:

Session type:

Badr Abdelmaksoud1,Mostafa Toam2
1faculty of medicine, zagazig university,2zagazig university

Introducing DPD Screening into Clinical Practice: The Sheffield Experience

Year:

Session type:

Alexander Burnett1,Alice Dewdney2
1Weston Park Hospital,2weston park hospital

Real-world experience of immune checkpoint inhibitor (ICPI) mediated pneumonitis in patients with metastatic cancer treated at Cambridge University Hospitals NHS Foundation Trust (CUHFT)

Year:

Session type:

Orthi Shahzad1,James Jones2,Sarah Welsh2,Jurgen Herre2,Pippa Corrie2
1University of Cambridge,2Cambridge University Hospitals NHS Foundation Trust

Cancer survival by stage at diagnosis in England.

Year:

Session type:

John Broggio1,Carolynn Gildea1,Kwok Wong1,Lorna Ushaw2,Marta Emmett1,Sarah Caul2,Sophie Finnigan1,Sophie John2,Yoryos Lyratzopoulos3
1Public Health England,2Office for National Statistics,3NCRAS

Evaluating kinome-wide resistance mechanisms to 3rd generation EGFR inhibitors

Year:

Session type:

Emma Fairweather1,Patrick Eyers1
1University of Liverpool

Is pelvic examination a key part of a patient’s gynaecological cancer diagnostic journey? A qualitative study of GPs and specialists.

Year:

Session type:

Pauline Williams1,Maggie Cruickshank1,Christine Bond1,Christ Burton2,Peter Murchie1
1University of Aberdeen,2University of Sheffield

Outcomes in patients age 70 and above treated with radical radiotherapy for Head & Neck Cancer

Year:

Session type:

Saurabh Borgaonkar1,Lisa Hay1,Claire Paterson1,Derek Grose1,Carolynn Lamb1,Stephano Schipani1,Christina Wilson1,Allan James1,Maureen Thomson1
1Beatson

Adolescent cancer risk exposures predict intermediate cancer risk exposures at age 24 years: A longitudinal analysis using ALSPAC data

Year:

Session type:

Caroline Wright1,Richard Martin1,Rona Campbell1,Ruth Kipping1,Matthew Hickman1,Jon Heron1
1University of Bristol

New Strategy for the Identification of Squamous Carcinoma Antigens that Induce Therapeutic Immune Responses in Tumor-Bearing Mice

Year:

Session type:

Edward Cohen1
1The University of Illinois at Chicago